Purple Biotech Ltd ADR (PPBT) Stock Price, Quote & News

Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 933 3121

Fax: 972 3 509 7196

Website: purple-biotech.com

Address:

4 Oppenheimer Street, Science Park, Rehovot, Israel

Winorbust Apr. 25 at 8:15 PM

$PPBT SAB basically means our company needs a new carrot to dangle in front of investors to justify -more- dilution and a much much longer timeframe, followed by more bonuses for management and another eventual reverse split

0 · Reply

PPBTPhoenix Apr. 25 at 6:59 PM

$PPBT just imagine if Purple had a working phone what they could do …at least we have a new SAB for a pre-clinical platform 😔

0 · Reply

Oxinternet Apr. 25 at 12:15 AM

$PPBT I got 5 grand to play with. These fuckers owe me - big time. It’s due a pump. If I choose not to go for it, it’ll hit 40 next week. If I do, they’ll do an offering and it’ll drop to 2. 😂

1 · Reply

Winorbust Apr. 24 at 7:16 PM

$PPBT I’m just waiting for the next crash to under $1 to see how Smitty says how bullish it is and makes excuses why his bosses at PPBT deserve more bonuses

0 · Reply

vinland Apr. 24 at 5:10 PM

$PPBT looks like that's about it for this mini pump, short 'em if you got 'em until next time.

0 · Reply

Winorbust Apr. 24 at 4:30 PM

$PPBT this is literally rinse and repeat. And some bulls don’t even see it haha. It’s the same crap they have been doing to dangle carrots and make excuses for bonuses and their salaries while they milk the company.

0 · Reply

Winorbust Apr. 24 at 4:29 PM

$PPBT Smitty isn’t an investor. He’s either a paid pumper or he works for the company. No -real- investor who opens their brokerage account and looks at their shares and averages here would be bullish -at all-

0 · Reply

Winorbust Apr. 24 at 4:28 PM

$PPBT more “board” seats so they can collect -more- money hahaha This just gets worse and worse of a scam.

0 · Reply

PPBTPhoenix Apr. 24 at 4:22 PM

$PPBT so Yael and Issac didn’t file Form 3’s with the rest of the board…. Anybody have any thoughts as to why?

3 · Reply

Duediligence20 Apr. 24 at 2:42 PM

$PPBT These idiots are so desperate they practically issue daily press releases now that cost upwards of 10k to register with the SEC. They all should lined up with a firing squad😡

0 · Reply

Purple Biotech Announces CEO Transition

Wed, 25 Feb 2026 16:20:00 -0500 - 2 months ago

Purple Biotech Announces Plan to Implement ADS Ratio Change

Dec 4, 2025, 7:00 AM EST - 5 months ago

Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

Nov 14, 2025, 8:00 AM EST - 5 months ago

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 29, 2025, 7:33 AM EDT - 6 months ago

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

Oct 20, 2025, 4:00 PM EDT - 6 months ago

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

Sep 5, 2025, 4:00 PM EDT - 8 months ago

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

Aug 27, 2025, 7:00 AM EDT - 8 months ago

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 6, 2025, 7:00 AM EDT - 9 months ago

Purple Biotech Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 7:00 AM EDT - 9 months ago

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Jun 23, 2025, 7:00 AM EDT - 10 months ago

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

May 21, 2025, 7:10 AM EDT - 1 year ago

Purple Biotech Reports First Quarter 2025 Financial Results

May 12, 2025, 7:30 AM EDT - 1 year ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Apr 28, 2025, 8:28 AM EDT - 1 year ago

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Mar 10, 2025, 8:57 AM EDT - 1 year ago

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Feb 18, 2025, 7:00 AM EST - 1 year ago

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Dec 5, 2024, 7:13 AM EST - 1 year ago

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 3, 2024, 8:23 AM EST - 1 year ago

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 2, 2024, 9:18 AM EST - 1 year ago

Why Is Purple Biotech Stock Trading Higher On Monday?

Nov 15, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 7:50 AM EST - 1 year ago

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Oct 25, 2024, 7:20 AM EDT - 1 year ago

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Aug 30, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 8:12 AM EDT - 1 year ago

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Jul 25, 2024, 7:35 AM EDT - 1 year ago

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Jul 2, 2024, 4:00 PM EDT - 1 year ago

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Jul 1, 2024, 9:00 AM EDT - 1 year ago

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Jun 27, 2024, 7:45 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Jun 1, 2024, 8:00 AM EDT - 2 years ago

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

May 21, 2024, 7:30 AM EDT - 2 years ago

Purple Biotech Reports First Quarter 2024 Financial Results

Apr 25, 2024, 7:00 AM EDT - 2 years ago

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Mar 14, 2024, 7:30 AM EDT - 2 years ago

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Mar 5, 2024, 7:55 AM EST - 2 years ago

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Feb 27, 2024, 7:00 AM EST - 2 years ago

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Feb 13, 2024, 7:00 AM EST - 2 years ago

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Feb 1, 2024, 7:30 AM EST - 2 years ago

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Dec 20, 2023, 8:05 AM EST - 2 years ago

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Dec 14, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Nov 21, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Reports Third Quarter 2023 Financial Results

Oct 19, 2023, 3:55 PM EDT - 2 years ago

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Purple Biotech Announces $5 Million Registered Direct Offering

Oct 6, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Oct 3, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Aug 22, 2023, 9:29 AM EDT - 2 years ago

Purple Biotech Reports Second Quarter 2023 Financial Results

Jul 11, 2023, 8:15 AM EDT - 3 years ago

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

May 16, 2023, 4:00 PM EDT - 3 years ago

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Apr 19, 2023, 8:15 AM EDT - 3 years ago

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Winorbust Apr. 25 at 8:15 PM

0 · Reply

PPBTPhoenix Apr. 25 at 6:59 PM

$PPBT just imagine if Purple had a working phone what they could do …at least we have a new SAB for a pre-clinical platform 😔

0 · Reply

Oxinternet Apr. 25 at 12:15 AM

1 · Reply

Winorbust Apr. 24 at 7:16 PM

$PPBT I’m just waiting for the next crash to under $1 to see how Smitty says how bullish it is and makes excuses why his bosses at PPBT deserve more bonuses

0 · Reply

vinland Apr. 24 at 5:10 PM

$PPBT looks like that's about it for this mini pump, short 'em if you got 'em until next time.

0 · Reply

Winorbust Apr. 24 at 4:30 PM

0 · Reply

Winorbust Apr. 24 at 4:29 PM

0 · Reply

Winorbust Apr. 24 at 4:28 PM

$PPBT more “board” seats so they can collect -more- money hahaha This just gets worse and worse of a scam.

0 · Reply

PPBTPhoenix Apr. 24 at 4:22 PM

$PPBT so Yael and Issac didn’t file Form 3’s with the rest of the board…. Anybody have any thoughts as to why?

3 · Reply

Duediligence20 Apr. 24 at 2:42 PM

$PPBT These idiots are so desperate they practically issue daily press releases now that cost upwards of 10k to register with the SEC. They all should lined up with a firing squad😡

0 · Reply

coinspitter Apr. 24 at 2:09 PM

$PPBT technically, it's holding up pretty well since last friday, so there could be some buying pressure behind. Boom or bust time, anyways!!!

0 · Reply

Reminderz Apr. 23 at 8:12 PM

$PPBT $BURU $VCIG $SFHG bel

0 · Reply

Duediligence20 Apr. 23 at 8:10 PM

$PPBT This what my investment in Purple Bio Shit looks like.

0 · Reply

Purplepayday Apr. 23 at 5:33 PM

$PPBT Well, Smitty might be right 🤷🏻‍♂️ This new SAB will probably make it a little easier for the Management to dilute and maybe get a dilutiv partner…. Let’s see, i still think they will lower the exercise price on the warrant’s 🤔

0 · Reply

BitterTwit2 Apr. 23 at 5:26 PM

$PPBT Has anyone figured out his average yet or are we still assuming he is a pumper without a position? I know my average is divorce worthy if she ever found out...

1 · Reply

Purplepayday Apr. 23 at 4:54 PM

$PPBT

0 · Reply

Shullders Apr. 23 at 4:47 PM

$PPBT The market has zero interest in this ticker. Basically zero volume

0 · Reply

Jafarafka Apr. 23 at 4:36 PM

$PPBT 🤡 Izzy, you can shove that advisory board up your ass, along with previous one! Fucking scammers

1 · Reply

Purplepayday Apr. 23 at 4:20 PM

$PPBT .. Maybe it’s time to average the losses again 🤷🏻‍♂️

0 · Reply

Purplepayday Apr. 23 at 4:11 PM

$PPBT Yes… It’s hard to be

0 · Reply

Smittysixty Apr. 23 at 2:35 PM

$PPBT And finally: Dr. Max Topp, a global leader in hematology and translational immunology. He played a key role in the early clinical development of blinatumomab — the first approved bispecific T‑cell engager. This is foundational expertise. If you’re building a next‑gen CD3 trispecific platform, this is the guy you want in the room. This SAB is not normal for a $7M microcap

1 · Reply

Smittysixty Apr. 23 at 2:34 PM

$PPBT Purple also added Dr. Alexander Shoushtari from Memorial Sloan Kettering — a clinical investigator involved in developing tebentafusp, one of the first approved T‑cell engagers in solid tumors. Read that again: He helped bring one of the only successful solid‑tumor T‑cell engagers to approval. People with that résumé don’t join weak platforms. They join programs with real potential. .

0 · Reply

Market Cap	5.83M
Revenue (ttm)	0.00
Net Income (ttm)	-26.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,700
Avg Vol	15,254
Day's Range	N/A - N/A
Shares Out	1.29M
Stochastic %K	60%
Beta	0.69
Analysts	Sell
Price Target	$30.00